Home Careers Contact

Price: 3.05

Change: - 0.05

Day High: 3.13
Day Low: 3.00
Volume: 627,668

4:00 PM ET | Oct 16, 2017
Delayed 20 min., by eSignal.

Shareholder Tools

Committee Composition

  Audit Nominating and Governance Compensation
Garheng Kong, M.D., Ph.D Chairman of the Board Member of Audit Committee   Committee Chair for Compensation Committee

Dr. Garheng Kong is a general partner at Sofinnova Ventures. Prior to joining Sofinnova in 2010, Dr. Kong was a general partner with Intersouth Partners where he had board involvement with most of Intersouth's life science companies, including his role as Chairman of the Board of Directors for Cempra Pharmaceuticals Inc. Dr. Kong has full-cycle investing experience, successfully sourcing, syndicating, managing and exiting investments. He also served as interim CEO for two Intersouth portfolio companies. Prior to Intersouth, he worked at GlaxoWellcome and McKinsey & Company. He received his M.D., Ph.D., in Biomedical Engineering, and M.B.A. from Duke University graduating at the top of his medical and business school classes. He also holds a B.S. in Chemical Engineering and a B.S. in Biological Sciences from Stanford University. He is active in the community and currently serves on the board of directors of the North Caroline Medical Device Organization, the SEBIO organization, the Corporate Chaplains of America and has served on the Duke University Medical Center Institutional Review Board. Dr. Kong is a current member of the faculty at the Duke School of Business as a Senior Scholar.

Holdings: 2,830 shares     View Transactions
Date Type Shares Traded Price Range
Oct 26, 2015 Buy 2,830 17.43
Feb 2, 2012 Statement of Ownership 0 n/a
David Zaccardelli, Pharm.D.      
Acting Chief Executive Officer

From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics, including chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations. Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He also served as director of clinical and scientific affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli received his Doctor of Pharmacy degree from the University of Michigan.

Richard Kent, M.D.     Member of Compensation Committee

Richard Kent, M.D. is a partner with Intersouth Partners. Prior to joining Intersouth, he served as CEO of Serenex, Inc., a venture-backed biotechnology company acquired by Pfizer in April 2008. He spent more than 25 years in the pharmaceutical industry, in a number of senior positions with the Burroughs Wellcome and GlaxoWellcome, eventually serving as Senior Vice President of Global Medical Affairs and Chief Medical Office of GlaxoSmithKline. Rick has supervised dozens of INDs and more than 20 successful NDAs (and equivalent submissions in Europe and the rest of the world) in a wide range of therapeutic areas including CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical Care, Cardiovascular and Oncology. He received his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, San Diego. He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University's medical faculty. He is board certified in both internal medicine and cardiology.
Holdings: 1,482,462 shares     View Transactions
Date Type Shares Traded Price Range
Aug 6, 2015 Acquisition (Non Open Market) 392 n/a
Mar 4, 2015 Option Execute 15,000 13.10
Feb 2, 2012 Statement of Ownership 0 n/a
David Gill Committee Chair for Audit Committee    

David Gill joined INC Research, a clinical research organization, in February 2011 as Chief Financial Officer after having served as a board member and Audit Committee chairman from 2007 to 2010. He was previously the Chief Financial Officer of TransEnterix, a private medical device company from March 2009 to February 2011. Mr. Gill was Chief Financial Officer and Treasurer of NxStage Medical, Inc, a publicly-traded dialysis equipment company, from July 2005 to November 2006 at which time he retired to pursue several board of director opportunities, including LeMaitre Vascular (LMAT) and Isotis Biologics (ISOT).

Mr. Gill served as Senior Vice President and Chief Financial Officer of CTI Molecular Imaging, Inc., a publicly-traded medical imaging company, from January 2002 to May 2005, before its sale. He served from February 2000 to March 2001 as Chief Financial Officer and Director, and from January 2001 to August 2001 as President, Chief Operating Officer, and Director, of Interland, Inc., a publicly-traded telecom-related company, before its sale. Previously, Mr. Gill served as the Chief Operating Officer and Chief Financial Officer of Novoste Corporation, a publicly-traded medical device company and as President of Dornier Medical Systems, a urologic equipment company.

Mr. Gill has led the IPO's of three companies and has raised more than $500 million in equity and $600 million in debt over his career. Mr. Gill holds a B.S. degree, cum laude, in Accounting from Wake Forest University and an M.B.A. degree, with honors, from Emory University, and was formerly a certified public accountant.

Dov A. Goldstein, M.D., M.B.A.   Committee Chair for Nominating and Governance Committee  

Dr. Goldstein serves as a Partner of Aisling Capital. Previously, Dr. Goldstein was Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals up until its acquisition by Pfizer. While at Vicuron Pharmaceuticals, he raised over $250 million dollars in an IPO, PIPE, Follow-on, and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first US and Italian public to public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr. Goldstein was Director of Venture Analysis at Healthcare Ventures. He also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital. Dr. Goldstein currently serves as a director of ADMA Biologics, Inc., Cempra Pharmaceuticals (NASDAQ: CEMP), Durata Therapeutics, Inc. and Esperion Therapeutics, Inc. Former investments include Topaz Pharmaceuticals (acquired by Sanofi). Dr. Goldstein received his M.D. from Yale School of Medicine. He received his M.B.A. from Columbia Business School and his B.S. with honors from Stanford University.

Holdings: 50 shares     View Transactions
Date Type Shares Traded Price Range
Mar 8, 2017 Sell 99,900 3.57
Mar 7, 2017 Sell 50,100 3.53
Jan 13, 2017 Sell 105,460 3.40
Jan 6, 2017 Sell 437,600 3.64
Jan 5, 2017 Sell 500,000 3.20
Mar 7, 2016 Disposition (Non Open Market) 999,955 n/a
Jan 4, 2016 Automatic Sell 842 30.06
Jan 4, 2016 Option Execute 842 n/a
Jun 22, 2015 Automatic Sell 50,000 35.74
Jun 22, 2015 Option Execute 50,000 n/a
May 14, 2015 Disposition (Non Open Market) 1,099,950 n/a
Feb 7, 2012 Buy 1,213,663 6.00
Feb 2, 2012 Statement of Ownership 0 n/a
John H. Johnson   Member of Nominating and Governance Committee  

John H. Johnson has more than two decades of biopharmaceutical and healthcare industry experience. John H. Johnson was appointed senior vice president and president of the oncology business unit, Eli Lilly and Company, effective November 1, 2009. Prior to this appointment, he had served as chief executive officer of ImClone Systems since August 2007 and was also a member of ImClone's board of directors until the company became a wholly-owned subsidiary of Lilly in November 2008. Previously, he served as company group chairman of Johnson and Johnson's Worldwide Biopharmaceuticals unit and was responsible for the biotechnology, immunology and oncology commercial businesses, including Centocor, Ortho Biotech Products and the Worldwide Strategic Marketing Group. Mr. Johnson began his career at Pfizer and then joined Johnson and Johnson in 2000 to help lead the Company into the anti-infectives market. He left Johnson and Johnson in 2000 to join Parkstone Medical Information systems as president and CEO, returning in 2002 as worldwide vice president, CNS/Psychiatry. He was then appointed president of Ortho Biotech Products and subsequently became responsible for Ortho Biotech Canada until he was named company group chairman in 2005. Mr. Johnson earned a B.S. degree from East Stroudsburg University of Pennsylvania.

Holdings: 10,000 shares     View Transactions
Date Type Shares Traded Price Range
May 23, 2014 Buy 10,000 9.10
Feb 2, 2012 Statement of Ownership 0 n/a
P. Sherrill Neff     Member of Compensation Committee

P. Sherrill Neff has served on our board of directors since September 2011. Mr. Neff founded Quaker Partners Management, L.P. in 2002 and has since served as a partner at the investment firm. From 1994 to 2002, Mr. Neff was President and Chief Operating Officer of Neose Technologies, Inc., a biopharmaceutical company, and a director from 1994 to 2003. From 1993 to 1994, he was Senior Vice President, Corporate Development at U.S. Healthcare. Prior to that time, Mr. Neff was managing director at investment bank Alex Brown & Sons from 1984 to 1993 and a corporate attorney at Morgan, Lewis & Bockius from 1980 to 1984. Mr. Neff holds a B.A. from Wesleyan University and a J.D. from the University of Michigan Law School. Mr. Neff serves on the board of directors of Resource Capital Corporation (NYSE: RSO), as well as several privately-held organizations including Biolex Therapeutics, Inc., Neuronetics, Inc., Optherion, Inc., RainDance Technologies, Inc. and Regado Biosciences, Inc. Mr. Neff also served on the board of directors of Amicus Therapeutics (Nasdaq: FOLD) from 1996 until 2011.
Holdings: 2,529,642 shares     View Transactions
Date Type Shares Traded Price Range
Oct 5, 2016 Disposition (Non Open Market) 1,000,000 n/a
Oct 5, 2016 Acquisition (Non Open Market) 2,488 n/a
Jun 19, 2013 Buy 265,000 7.00
Feb 8, 2012 Buy 1,189,805 6.00
Feb 2, 2012 Statement of Ownership 0 n/a
Michael Dougherty Member of Audit Committee Member of Nominating and Governance Committee  

Michael R. Dougherty was chief executive officer and member of the board of directors of Kalidex Pharmaceuticals, Inc., a start-up anti-infective company, prior to his appointment to Cempra’s board of directors. He previously served as president and chief executive officer and board member of Adolor Corp., a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products, until December 2011. He joined Adolor as senior vice president of commercial operations in November 2002, and until his appointment as president and chief executive officer in December 2006, served in a number of capacities, including chief operating officer and chief financial officer. From November 2000 to November 2002, Mr. Dougherty was also president and chief operating officer of Genomics Collaborative, Inc., a privately held functional genomics company. He also held senior positions at Genaera Corporation and Centocor, Inc. He currently serves as a member of the board of directors of Viropharma, Inc and Biota Pharmaceuticals, Inc.  Mr. Dougherty received a B.S. from Villanova University.

Chair of the Board = Chair of the Board Committee Chair = Chair of the Committee Committee Member = Member

Stock transaction information provided by EDGAR Online. Cempra, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.